The following is a summary of the Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript:

Financial Performance:

• Addex Therapeutics reported a minor reported income of $0.1 million in Q2 2024, compared to $0.6 million in Q2 2023.

• Major financial transaction includes the launch of Neurosterix with a $63 million Series A funding, securing CHF 5 million and a 20% equity for Addex.

• The financial outlook emphasizes careful management of research costs aligned with ongoing collaborations, notably with Indivior, which supports stable financial expenditures in R&D.

Business Progress:

• Achievements include the successful launch of Neurosterix, securing significant funding and strategic equity.

• Progress in the GABAB PAM program with Indivior selecting a development candidate aimed at treating substance use disorders.

• Expansion of dipraglurant's potential indications to include brain injury recovery, following exploration of its efficacy in post-stroke rehabilitation.

• Independent advancement of a GABAB PAM for chronic cough, poised for IND studies in 2025.

Opportunities:

• The Neurosterix transaction offers a strategic opportunity to finance complex R&D without diluting shareholder value.

• Ongoing development in GABAB PAM offers new therapeutic opportunities in substance use disorders.

• Potential to meet the unmet medical need in chronic cough and brain injury categories, leveraging the differentiated profiles of dipraglurant and the selected GABAB PAM candidates.

Risks:

• Regulatory and developmental risks as programs move towards IND studies, particularly the GABAB PAM candidate selections and repositioned uses of dipraglurant.

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.